Thomas J. Schall, President and CEO at ChemoCentryx, Inc. (CCXI), sold 300,000 shares at $12.26 ($3.6M) on 2018-05-16, disclosed to the SEC on 2018-05-17.
Open-market sale of $3.6M CCXI by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.32 | 100,000 | $1.1M | 31.6% |
| 2 | $12.26 | 82,202 | $1.0M | 28.2% |
| 3 | $12.26 | 82,202 | $1.0M | 28.2% |
| 4 | $12.14 | 17,798 | $216K | 6.0% |
| 5 | $12.14 | 17,798 | $216K | 6.0% |
| Total | $11.93 avg | 300,000 |
| $3.6M |
| 100% |
| Filing → |
| IMRX | BUY | 2025-06-18 | $179K | — | Filing → |
| IMRX | BUY | 2024-03-25 | $7K | — | Filing → |
| CCXI | SELL | 2022-08-08 | $6.5M | — | Filing → |